Eikon Therapeutics, Inc.

About Eikon Therapeutics, Inc.

Eikon Therapeutics is focused on advancing breakthrough therapeutics through the purposeful integration of science and engineering. Their mission is to create innovative therapies and deliver important new medicines for human diseases by leveraging existing tools and inventing new solutions when necessary.

Products & Services

Therapeutic Pipeline:A growing pipeline aimed at delivering new medicines to address serious illnesses.

Platform:A proprietary technology platform that integrates diverse capabilities and engineering skills to achieve superior results in drug discovery.

Specialties

Scientific Research Data Analytics Engineering Drug Discovery Clinical Development oncology drug discovery clinical development single-molecule imaging machine learning synthetic lethality immune modulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: IPO T: - FT: IPO	A: 381000000 MR: - FA: approximately $381 million FAN: 381000000	D: 2026-02-04 FD: 2026-02-04	5 investors
2	RT: Series D T: - FT: Series D	A: 350700000 MR: - FA: 350.7 million FAN: 350700000	D: 2025-02-26 FD: 2025-02-26	11 investors

IPO Latest

2026-02-04

$381.0M

5 investors (Pro only)

Series D 2025-02-26

$350.7M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Roger Perlmutter

Chief Executive Officer

R

Roy Baynes

Chief Medical Officer

A

Alfred Bowie

Chief Financial Officer

R

Russ Berman

Chief Technology Officer

M

Mike Klobuchar

Chief Operating Officer

B

Ben Thorner

Chief Business Officer and General Counsel

View 8 more team members with Pro

Unlock Full Team Directory

Recent News